Hidradenitis suppurativa (HS), a chronic, inflammatory, relapsing disease of the apocrine glands in the skin, commonly occurs in women aged 20 to 40 years. Patients typically present with discomfort and/or itching associated with papules or nodules that may recur and lead to abscess formation and sinus tracts. Recent reports have demonstrated that adalimumab, a tumor necrosis factor (TNF) antagonist, may be effective in the treatment of patients with HS who have failed conventional therapy. The authors describe 3 patients who experienced the resolution of skin lesions associated with HS after treatment with adalimumab. The patients found this treatment to be convenient, as they could administer the therapy at home, and 1 patient was able to avoid surgical intervention through use of TNF-antagonist therapy. Adalimumab may resolve symptoms of HS when conventional therapy fails. More studies are necessary to investigate the efficacy and safety of adalimumab for the treatment of HS.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hidradenitis Suppurativa Surgery Complication Rates Among Patients With Obesity or Diabetes or Who Smoke: A Review.
JAMA Dermatol
January 2025
Department of Dermatology, School of Medicine, University of North Carolina at Chapel Hill.
Importance: Surgery is frequently required for hidradenitis suppurativa (HS) treatment, but the impact of common comorbidities such as obesity, diabetes, and smoking on outcomes has been sparsely studied.
Observations: A total of 12 studies met final inclusion criteria for investigating complication rates associated with at least 1 comorbidity. Complication rates were associated with obesity in 3 of 10 studies.
Serum Immunoglobulin G Levels and Nicastrin Variation in Hidradenitis Suppurativa.
JAMA Dermatol
January 2025
Centre for Molecular Medicine and Biobanking, University of Malta, Malta.
Importance: Variation in nicastrin (NCSTN) is associated with a monogenic subtype of hidradenitis suppurativa. Dysregulation of humoral immunity has been suggested as a potential mechanistic link between NCSTN variation and hidradenitis suppurativa. There is a paucity of biomarkers that can predict disease-associated variation.
View Article and Find Full Text PDFThe Use and Impact of Patient Support Groups in Hidradenitis Suppurativa Patients.
J Cutan Med Surg
January 2025
Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Interleukin-17: A pleiotropic cytokine implicated in inflammatory, infectious, and malignant disorders.
Cytokine Growth Factor Rev
January 2025
MCW Cancer Center and Genomic Sciences and Precision Medicine Center, Medical College of Wisconsin, Milwaukee, WI, USA; WIN Consortium, Paris, France; University of Nebraska, Lincoln, NE, USA. Electronic address:
IL-17A, referred to as IL-17, is the founding member of a family of pro-inflammatory cytokines, including IL-17B, IL-17C, IL-17D, IL-17E (or IL-25), and IL-17F, which act via receptors IL-17RA to IL-17RE, and elicit potent cellular responses that impact diverse diseases. IL-17's interactions with various cytokines include forming a heterodimer with IL-17F and being stimulated by IL-23's activation of Th17 cells, which can lead to inflammation and autoimmunity. IL-17 is implicated in infectious diseases and inflammatory disorders such as rheumatoid arthritis and psoriasis, promoting neutrophil recruitment and anti-bacterial immunity, but potentially exacerbating fungal and viral infections, revealing its dual role as protective and pathologic.
View Article and Find Full Text PDFThe effect of the antibody-mediated immune responses on hidradenitis suppurativa: a mendelian randomization study.
Arch Dermatol Res
January 2025
Department of Dermatology, General Hospital of Northern Theater Command, Shenyang, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!